CRF Bracket updates eConsent solution to support virtual studies

By Melissa Fassbender contact

- Last updated on GMT

(Image: Gett/oatawa)
(Image: Gett/oatawa)

Related tags: CRF Bracket, Clinical trial management

CRF Bracket’s eConsent solution now supports remote consenting – as the demand for virtual clinical trials has increased steadily over recent years.

The electronic consent (eConsent) solution, TrialConsent, can integrate with electronic clinical outcome assessment (eCOA) or stand alone.

Jeff Lee, product lead, patient engagement and eConsent at CRF Bracket, said the new secure password-protected login account feature for patients is important. “Optimizing how this gets handled allows for the patient to pause/resume during the consenting process, which is a key patient-centric design feature,”​ he told us.

This login feature – not available on the company's other eConsent systems – eases the patient experience during re-consent, said Lee. He added, “Patients and their families are also given the opportunity to flag any concerns or questions on the documentation and resolve these before providing their consent on a trial.”​  

Since the remote study model was pioneered by Pfizer in 2012, and given “an additional bolt of interest”​ by ResearchKit in 2015, Lee said most initiatives have had “fairly modest ambitions,”​ targeting observational studies “where the expectations for study conduct are more forgiving.”

Still, demand for remote studies has steadily increased over recent years, he said.

“Increasingly, sponsors have come to recognize that fully virtual studies are less realistic. It’s more likely that studies will become ‘semi-virtual,’ where some of the visits are supported remotely, but some still occur at the study site,”​ explained Lee.

He added, “In a way, this realization takes the pressure off the industry to fully resolve challenging issues associated with remotely joining a study, such as how to remotely verify the patient’s identity and direct-to-patient drug supply.”

Lee said this should prompt more use of remote study activities in standard interventional studies. 

“Since we have randomization, eConsent, patient engagement, eCOA, drug supply management, all within a single organization, we feel a responsibility to push ourselves to solve these difficult challenges and help the industry achieve breakthroughs around fully or partially virtual studies,”​ he added.

Moving forward, Lee said the company’s roadmap includes “multiple additional enhancements”​ to its current support of the remote study model.

CRF Bracket recently closed its first full quarter as a combined entity, after the private equity firm behind Bracket purchased​ CRF Health in July 2018. The company saw more than a 20% increase in new clinical trial business​ in the quarter and will “aggressively look for partners” ​from its current and future customers, CEO Mike Nolte told us at the time.

Related news

Show more

Related products

RACE Act Prompts Pediatric Oncology Trials

RACE Act Prompts Pediatric Oncology Trials

PRA Health Sciences | 04-May-2020 | Technical / White Paper

Many providers prescribe drugs off-label to pediatric patients, even though there have been few pediatric trials for many of these drugs. In response,...

Global Clinical Trial Lab Services

Global Clinical Trial Lab Services

Q2 Solutions | 01-Apr-2020 | Product Presentation

As a leading global lab services partner, we provide operational excellence, scientific leadership and innovation through technology. We offer end-to-end...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 01-Mar-2020 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

What do big pharma companies spend on R&D?

What do big pharma companies spend on R&D?

Zymewire | 15-Aug-2019 | Technical / White Paper

The free Big Pharma R&D Spend report examines the financial performance and research & development investments of the top 25 pharmaceutical companies...

Related suppliers

Follow us


View more